Posted: 15 January 2026
BioNTech SE has outlined its strategic updates and priorities for 2026, with the year positioned as a milestone-rich period for its oncology pipeline, during an update delivered at the J.P. Morgan Healthcare Conference in San Francisco.
Strong momentum has been reported to have been carried into 2026 following progress across research and development, partnerships, acquisitions and financial performance in 2025. BioNTech has been described as having been successfully positioned as a late-stage biopharmaceutical company, with multiple programmes approaching critical inflection points. The update was delivered by Professor Ugur Sahin during a presentation at the conference on Tuesday, January 13, 2026.
“We concluded 2025 with strong momentum, driven by our execution in research and development, partnerships, acquisitions, and our financial strength,” said Professor Ugur Sahin, Chief Executive Officer and Co-Founder. “We see 2026 as a year when science translates into tangible results.”
The oncology pipeline has been reported to span immunomodulators, antibody-drug conjugates and mRNA cancer immunotherapies, with a strategic shift underway from modality-driven development toward disease-specific programmes. Focus areas have been stated to include lung, breast, gynaecologic, gastrointestinal and genitourinary cancers.
Late-stage development has been highlighted as a central priority, with more than 25 Phase 2 and Phase 3 oncology trials reported to be ongoing. During 2026, six additional Phase 3 trials are expected to be initiated, bringing the total number of Phase 3 studies to 15 by year end. Seven late-stage clinical data readouts have been anticipated across multiple tumour types.
Combination therapy development has also been emphasised, with more than ten novel-novel combination trials reported to be in progress. These studies have been described as informing dose selection and anti-tumour activity to support future late-stage development.
BioNTech’s financial position has been reported to have remained strong, supported by COVID-19 vaccine revenues and strategic partnerships. Cash, cash equivalents and security investments have been stated to total approximately €17.2 billion as of 31 December 2025, enabling continued investment in research and development.
Additional late-stage trial readouts extending through 2030 and beyond have been outlined as creating multiple potential launch opportunities, supporting BioNTech’s evolution into a multi-product oncology company.
